Shots:
- BioPorto has reported the US launch of the ProNephro acute kidney injury (AKI) test through its collaboration with Roche, following its FDA 510(k) clearance on Roche’s cobas c 501 analyzers for hospital clinical laboratories
- ProNephro AKI (NGAL) is an AKI biomarker test for pediatric use (3mos.–21yrs.), which helps identifying ICU pts at risk of developing or having persistent mod. to sev. AKI within 48–72hrs.
- ProNephro AKI (NGAL) will expand to additional standard lab chemistry systems, incl. cobas c 502, Pro & Pure, & enroll its first patient in a study to obtain FDA clearance for use in pts over 22yrs.
Ref: GlobeNewswire | Image: BioPorto | Press Release
Related News:- Airiver Medical Receives the US FDA’s IDE Approval to Study Airiver Pulmonary Drug Coated Balloon for Benign Central Airway Stenosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
